Sivu 13 |
High infant mortality is also a major transfusion-transmitted infections. There is an urgent need for developing problem. Medix Biochemica provides tools to help Indian midwives monitor inexpensive strategies for safe blood pregnancies. one of the tests detects in transfusion," says group leader Navin five minutes if the foetal membranes Khanna of the Recombinant gene have ruptured prematurely. Another Products laboratory at the Internais a simple bedside dipstick test to tional Centre for genetic Engineering measure whether and Biotechnolthe mother is merely ogy in new Delhi. experiencing normal "The World FInlAnD IS A preterm contractions Health organizaWoRlD lEADER or whether she is tion recommends In DEVEloPIng about to give birth. that, at a mininoVEl DIAgnoSTIC Furthermore, Ani mum, all blood for ConCEPTS. Biotech has developed transfusion should two kinds of rapid be screened for immunodiagnostic HIV, hepatitis B tests for heart attacks, which cause and C, malaria and syphilis. The IndoFinnish collaboration aims to develop 1.5 million deaths in India each year. one predicts the probability of a an affordable, robust, rapid, simple heart attack; the other diagnoses it and sensitive system for testing these infectious diseases in blood banks," he afterwards, based on cells that have died from lack of oxygen. explains. An all-in-one, ready-to-use hospital shipped to a far-off location by helicopter. Now how about that? By LEENA KOSKENLAAKSO illuStration By PETRI TURUNEN { } hospital in a container E Making things happen Khanna has been pleasantly surprised by the enthusiasm of Finnish researchers, and the high level of natural synergy between colleagues. "Finland is a world leader in developing novel diagnostic concepts. The University of Turku has a highly focused research team and a critical mass of researchers to make a significant impact in this area. The Finnish researchers have a special ability to make things happen, and our research group has benefited immensely from this collaboration." Khanna hopes to see the partnership strengthened with a long-term exchange programme for students. local presence needed Aimo Niskanen, managing director of Ani Biotech, is keen for the company to establish a sales office in India. "The lesson we have learned is that significant business cannot be done in India without a local presence," comments niskanen. The company's main markets are currently the European Union, China and Japan. Ismo Råman, CEo of Medix Biochemica, says that special products and high quality make Finnish rapid diagnostic products globally competitive. His company's main markets are the European Union, Japan and Korea, but India is an emerging contender. "There is demand for Finnish products amongst affluent Indian middle-class consumers. local production is the answer in the lower income segment," Råman concludes. www.anibiotech.fi www.medixbiochemica.fi xpandable containers serving as health care clinics or even fully functional hospitals with laboratory facilities are manufactured in Rautalampi in central Finland. Morehouse's termite-proof, multi-purpose modules can be used in demanding field conditions all around the world. "The containers are built and equipped to customer specifications from beginning to end," says managing director Pekka tuomela. Morehouse's container suitable for hospital use is a 20-foot sea container which, when opened out, triples its volume, expanding into a utility area of 40 square metres. The floor space can be divided into several rooms centred around a corridor. The container can be used on its own, or as a combination of several adjacent modules. The units can be brought to the location by truck, sea, rail, plane or helicopter. "Our modules have been used all around the world by customers such as the Finnish Defence Forces, who use them in international peace-keeping operations. The containers are easy to install and relocate. Assembling a container unit takes only 40 minutes." www.morehouse.fi Saving babies In India, diarrhoea caused by the dangerous rotavirus kills large numbers of infants every year. Finnish diagnostics company Ani Biotech has developed tests for identifying dangerous forms of diarrhoea. Sister company Ani labsystems produces tests for screening and identification of metabolic disorders in newly born babies. All of these blood-based tests are being or starting to be used in India. 13
Page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Page 10
Page 11
Page 12
Page 13
Page 14
Page 15
Page 16
Page 17
Page 18
Page 19
Page 20
Page 21
Page 22
Page 23
Page 24
Page 25
Page 26
Page 27
Page 28
Page 29
Page 30
Page 31
Page 32
Page 33
Page 34
Page 35
Page 36
Page 37
Page 38
Page 39
Page 40
Page 41
Page 42
Page 43
Page 44
|
|
|
Why do I see this page ?
Your Flash Player is older than version 7 or Javascript is not enabled. What you see is the raw text of the publication.
To read this Digipaper-publication install/update your Flash Player from this link or enable Javascript.
|
 |
For proper operation Digipaper-publication needs Flash Player version 7 or newer.
Install the latest version of Flash Player from this link. |
|